CH Biotech R&D Co., Ltd. (6534) Stock Statistics & Valuation Metrics
Total Valuation
CH Biotech R&D Co., Ltd. has a market cap or net worth of TWD 8.30B. The enterprise value is TWD 8.94B.
- Market Cap
- TWD 8.30B
- Enterprise Value
- TWD 8.94B
Share Statistics
CH Biotech R&D Co., Ltd. has 97,083,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 97,083,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
CH Biotech R&D Co., Ltd.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 15.16%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.13
- Return on Invested Capital (ROIC)
- 15.16%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 9.10M
- Profits Per Employee
- 2.32M
- Employee Count
- 200
- Asset Turnover
- 0.51
- Inventory Turnover
- 3.02
Valuation Ratios
The current PE Ratio of CH Biotech R&D Co., Ltd. is 15.28. CH Biotech R&D Co., Ltd.’s PEG ratio is 0.50.
- PE Ratio
- 15.28
- PS Ratio
- 4.60
- PB Ratio
- 3.59
- Price to FCF
- 11.65
- Price to Operating Cash Flow
- 10.54
- PEG Ratio
- 0.50
Income Statement
In the last 12 months, CH Biotech R&D Co., Ltd. had revenue of 1.82B and earned 463.79M in profits. Earnings per share was 4.51.
- Revenue
- 1.82B
- Gross Profit
- 1.36B
- Operating Income
- 623.13M
- Pretax Income
- 568.87M
- Net Income
- 463.79M
- EBITDA
- 837.25M
- Earnings Per Share (EPS)
- 4.51
Cash Flow
In the last 12 months, operating cash flow was 897.01M and capital expenditures -155.64M, giving a free cash flow of 741.37M billion.
- Operating Cash Flow
- 897.01M
- Free Cash Flow
- 741.37M
- Free Cash Flow per Share
- 6.72
Dividends & Yields
CH Biotech R&D Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 6.21%
- Dividend Per Share
- ―
- Dividend Yield
- 6.21%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 8.60%
- Earnings Yield
- 6.05%
Stock Price Statistics
- Beta
- 0.07
- 52-Week Price Change
- -14.50%
- 50-Day Moving Average
- 91.49
- 200-Day Moving Average
- 89.64
- Relative Strength Index (RSI)
- 28.02
- Average Volume (3m)
- 59.48K
Important Dates
CH Biotech R&D Co., Ltd. upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
CH Biotech R&D Co., Ltd. as a current ratio of 1.21, with Debt / Equity ratio of 24.73%
- Current Ratio
- 1.21
- Quick Ratio
- 1.00
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 0.32
- Interest Coverage Ratio
- 36.73
Taxes
In the past 12 months, CH Biotech R&D Co., Ltd. has paid 105.08M in taxes.
- Income Tax
- 105.08M
- Effective Tax Rate
- 0.18
Enterprise Valuation
CH Biotech R&D Co., Ltd. EV to EBITDA ratio is 11.51, with an EV/FCF ratio of 11.93.
- EV to Sales
- 4.71
- EV to EBITDA
- 11.51
- EV to Free Cash Flow
- 11.93
- EV to Operating Cash Flow
- 9.86
Balance Sheet
CH Biotech R&D Co., Ltd. has TWD 640.73M in cash and marketable securities with TWD 868.36M in debt, giving a net cash position of -TWD 227.63M billion.
- Cash & Marketable Securities
- TWD 640.73M
- Total Debt
- TWD 868.36M
- Net Cash
- -TWD 227.63M
- Net Cash Per Share
- -TWD 2.34
- Tangible Book Value Per Share
- TWD 25.97
Margins
Gross margin is 83.68%, with operating margin of 35.02%, and net profit margin of 30.39%.
- Gross Margin
- 83.68%
- Operating Margin
- 35.02%
- Pretax Margin
- 36.89%
- Net Profit Margin
- 30.39%
- EBITDA Margin
- 40.94%
- EBIT Margin
- 35.02%
Analyst Forecast
The average price target for CH Biotech R&D Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 6.31%
- EPS Growth Forecast
- 31.07%
